HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Free via Open Access: OA OA Abstract Full Text (PDF) Supplementary table Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hedayati, M. T. Articles by Denning, D. W. Search for Related Content PubMed PubMed Citation Articles by Hedayati, M. T. Articles by Denning, D. W. Agricola Articles by Hedayati, M. T. Articles by Denning, D. W.

Aspergillus flavus: human pathogen, allergen and mycotoxin producer

¹ Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
² School of Medicine, The University of Manchester and Wythenshawe Hospital, Southmoor Road, Manchester M23 9PL, UK

Correspondence
D. W. Denning
ddenning{at}manchester.ac.uk

	ABSTRACT

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Aspergillus infections have grown in importance in the last years. However, most of the studies have focused on Aspergillus fumigatus, the most prevalent species in the genus. In certain locales and hospitals, Aspergillus flavus is more common in air than A. fumigatus, for unclear reasons. After A. fumigatus, A. flavus is the second leading cause of invasive aspergillosis and it is the most common cause of superficial infection. Experimental invasive infections in mice show A. flavus to be 100-fold more virulent than A. fumigatus in terms of inoculum required. Particularly common clinical syndromes associated with A. flavus include chronic granulomatous sinusitis, keratitis, cutaneous aspergillosis, wound infections and osteomyelitis following trauma and inoculation. Outbreaks associated with A. flavus appear to be associated with single or closely related strains, in contrast to those associated with A. fumigatus. In addition, A. flavus produces aflatoxins, the most toxic and potent hepatocarcinogenic natural compounds ever characterized. Accurate species identification within Aspergillus flavus complex remains difficult due to overlapping morphological and biochemical characteristics, and much taxonomic and population genetics work is necessary to better understand the species and related species. The flavus complex currently includes 23 species or varieties, including two sexual species, Petromyces alliaceus and P. albertensis. The genome of the highly related Aspergillus oryzae is completed and available; that of A. flavus in the final stages of annotation. Our understanding of A. flavus lags far behind that of A. fumigatus. Studies of the genomics, taxonomy, population genetics, pathogenicity, allergenicity and antifungal susceptibility of A. flavus are all required.

	Introduction

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
The aspergilli have always been a factor in the human environment. Micheli was the first to distinguish stalks and spore heads, but it was not until the middle of the 19th century that these fungi began to be recognized as active agents in decay processes, as causes of human and animal disease and as fermenting agents capable of producing valuable metabolic products (Raper & Fennel, 1965).

First described by Link (1809), Aspergillus flavus is the name now used to describe a species as well as a group of closely related species. A. flavus is second only to A. fumigatus as the cause of human invasive aspergillosis. In addition, it is the main Aspergillus species infecting insects (Campbell, 1994), and it is also able to cause diseases in economically important crops, such as maize and peanuts, and to produce potent mycotoxins. The purpose of this review is to summarize the current knowledge about this important group of fungi.

	Ecology and geographical distribution

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Like other Aspergillus species, A. flavus has a worldwide distribution. This probably results from the production of numerous airborne conidia, which easily disperse by air movements and possibly by insects. Atmosphere composition has a great impact on mould growth, with humidity being the most important variable (Gibson et al., 1994). A. flavus grows better with water activity (a_w) between 0.86 and 0.96 (Vujanovic et al., 2001). The optimum temperature for A. flavus to grow is 37 °C, but fungal growth can be observed at temperatures ranging from 12 to 48 °C. Such a high optimum temperature contributes to its pathogenicity in humans.

Soil
A. flavus appears to spend most of its life growing as a saprophyte in the soil, where it plays an important role as nutrient recycler, supported by plant and animal debris (Scheidegger & Payne, 2003). The ability of A. flavus to survive in harsh conditions allows it to easily out-compete other organisms for substrates in the soil or in the plant (Bhatnagar et al., 2000). The fungus overwinters either as mycelium or as resistant structures known as sclerotia. The sclerotia either germinate to produce additional hyphae or they produce conidia (asexual spores), which can be further dispersed in the soil and air.

Outdoor air
A. flavus has been particularly prevalent in the air of some tropical countries (Moubasher et al., 1981; Abdalla, 1988; Gupta et al., 1993; Adhikari et al., 2004). Climatic conditions markedly influence the prevalence of A. flavus in outdoor air. As an example, two Spanish studies revealed very different results. In Barcelona A. flavus and A. niger were the most frequent airborne aspergilli (Calvo et al., 1980) whereas in Madrid A. fumigatus was the most prevalent species (54 %) (Guinea et al., 2005). Comparing Aspergillus species in the air in London, Paris, Lyon and Marseille, Mallea et al. (1972) showed that A. glaucus and A. versicolor group predominated in southern France. On the other hand, A. fumigatus represented more than 35 % of the isolates recovered from Paris and London, whereas A. glaucus group never exceeded 20 % (Mallea et al., 1972). In Brussels, A. fumigatus was the most common Aspergillus species whereas A. flavus represented only 1 % of isolates (Vanbreuseghem & Nolard, 1985).

Home and hospital air
The presence of Aspergillus in the air is a major risk factor for both invasive and allergic aspergillosis (Denning, 1998). Accordingly, several outbreaks of invasive aspergillosis have been associated with construction and/or renovation activities in and around hospitals (Sarubbi et al., 1982; VandenBergh et al., 1999), activities that markedly increase the number of spores in the air. Also, in several studies the link between infection by A. flavus and the contamination of the environment was clearly demonstrated by molecular typing methods (Rath & Ansorg, 1997; Diaz-Guerra et al., 2000) (see below). In two studies from Iran, A. flavus was the most prevalent Aspergillus species to be recovered from the air of hospital wards and homes (Zaini & Hedayati, 1995; Hedayati et al., 2005).

Water
Fungi in drinking water may alter the taste and odours of the water. Health problems are possible, including mycotoxin exposure, direct infection and allergy. More studies are needed on this subject. Surveys of fungi in drinking water have recovered many different taxa, including A. flavus (Gottlich et al., 2002; Goncalves et al., 2006) and in particular A. fumigatus (Warris et al., 2001; Anaissie et al., 2002). Contamination tends to arise from surface reservoirs and not from deep ground wells (Warris et al., 2001). This variation is often attributed to factors such as raw water source (surface versus well), water temperature patterns, treatment patterns and maintenance of distribution systems. Additionally, it was reported that fungi can pass through treatment processes by means of leaks in the system, or from air in contact with water stored in distribution system reservoirs, and can even survive water disinfection with chlorine (Niemi et al., 1982). Interestingly, Paterson et al. (1997) detected aflatoxin in water and identified A. flavus from a cold-water storage tank.

	Genome

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
The recent sequencing of the A. oryzae genome sequence provides an excellent tool for researchers to gain insight into the basic biology of this organism (Machida et al., 2005; Galagan et al., 2005). The sequencing of A. flavus (NRRL 3357, Geiser Group 1C) is in progress, and will provide a rich source of comparative data. The primary assembly indicates that the A. flavus genome is 36.3 Mb in size and consists of eight chromosomes and 13 071 predicted genes. The mean gene length is 1384 bp (Yu et al., 2005). A. flavus is genetically almost identical to A. oryzae. Comparative genomics will be particularly interesting as A. flavus is a common environmental organism whilst the sequence strain of A. oryzae is a ‘domesticated’ fungus, having been used in soy fermentation for thousands of years, and rarely causes disease.

	Taxonomy

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Classically, the systematics of Aspergillus and its associated teleomorphs have been based primarily on differences in morphological and cultural characteristics (Raper & Fennel, 1965; Samson et al., 2000). Petromyces alliaceus and P. albertensis are the only two sexually reproducing species (teleomorphs) classified in Aspergillus flavus complex (Table 1) (Frisvad et al., 2005). They were characterized by ascomata produced within closed sclerenchymatous stromata. The genus Petromyces belongs to the family Trichocomaceae of the order Eurotiales of Ascomycetes. Moreover, the taxonomy of the flavus complex group is further complicated by the existence of morphological divergence amongst isolates of the same species (Klich & Pitt, 1988).

Restriction fragment length polymorphism (RFLP) has been used to distinguish between A. flavus and A. oryzae and to infer phylogenetic relationships (Bruns et al., 1991; Montiel et al., 2003). Moody & Tyler (1990) demonstrated that restriction profiles of purified mitochondrial DNA can distinguish A. flavus Link, A. parasiticus Speare and A. nomius Kurtzman et al. However, for routine identification of Aspergillus isolates it is desirable to detect mitochondrial DNA RFLP without first separating the mitochondrial DNA from the nuclear DNA (Bruns et al., 1991).

Wang et al. (2001) described the use of partial sequences of the mitochondrial cytochrome b gene (402 bp) to differentiate 77 isolates in the Aspergillus flavus complex into seven DNA types (D-1 to D-7). A. sojae were defined as D-1, A. parasiticus as D-2, A. flavus and A. oryzae were grouped together as D-4, A. tamarii was defined as D-5 and A. nomius as D-7. Furthermore, D-3 was found to be closely related to A. parasiticus (D-2), also including one strain that had been deposited as A. flavus var. flavus. DNA type D-6 included one strain that was identified as A. flavus and was closely related to A. tamari. Peterson (2000) differentiated 17 type strains in the flavus complex based on rDNA sequence analysis. These included A. flavus, A. oryzae, A. parasiticus, A. sojae, A. terricola var. americana, A. subolivaceus, A. kambarensis, A. flavus var. columnaris, A. thomii, A. tamarii, A. caelatus, A. leporis, A. nomius, Petromyces alliaceus, A. avenaceus, A. zonatus and A. clavatoflavus (Table 1). The author also indicated that A. zonatus and A. clavatoflavus were not phylogenetically part of the flavus complex.

Single-strand conformation polymorphism of internal transcribed spacer (ITS) regions has also been used as a genetic approach to differentiate species in the flavus complex (Kumeda & Asao, 1996). This complex seems to comprise distinct clades (Rigo et al., 2002). The three main clades (P. alliaceus, A. flavus and A. tamarii) could also be distinguished based on colony colour and their ubiquinone system. Based on ITS sequences A. robustus, A. caelatus, A. lanosus, A. albertensis, A. coremiiformis, A. flavofurcatis, A. toxicarius, A. terricola var. indica, A. terricola and the species mentioned by Peterson (2000) were all located in Aspergillus flavus complex. In addition, A. pseudotamarii and A. bombycis were found to be closely related to A. caelatus and A. nomius, respectively (Table 1). Rigo et al. (2002) suggested that A. zonatus and A. clavatoflavus should be excluded from Aspergillus flavus complex, a suggestion previously made by Kozakiewicz (1989), based on scanning electron microscopic studies. Recently, Frisvad et al. (2005) found that A. toxicarius resembles A. parasiticus but differs in at least three sequence differences in the ITS regions, as compared to four strains of A. parasiticus. Usually, the presence of three or more sequence differences in ITS regions is an indication of a different species. A. zhaoqingensis was considered the same as A. nomius in this study (Frisvad et al. 2005).

	Identification

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Accurate species identification within Aspergillus flavus complex remains difficult due to overlapping morphological and biochemical characteristics (Table 1). In general, A. flavus is known as a velvety, yellow to green or brown mould with a goldish to red-brown reverse (Fig. 1). The conidiophores are variable in length, rough, pitted and spiny. They may be either uniseriate or biseriate. They cover the entire vesicle, and phialides point out in all directions (Fig. 2). Conidia are globose to subglobose, conspicuously echinulate, varying from 3.5 to 4.5 µm in diameter. Based on the characteristics of the sclerotia produced, A. flavus isolates can be divided into two phenotypic types. The S strain produces numerous small sclerotia (average diameter <400 µm). The L strain produces fewer, larger sclerotia (Cotty, 1989). Within the S strain, some isolates, termed SB, produce only B aflatoxins, whilst others, named SBG, produce both B and G aflatoxins (Cotty, 1989). The S strain isolates have been referred to as atypical (Nozawa et al., 1989), microsclerotium producing (Saito & Tsurata, 1993) and A. flavus var. parvisclerotigenu (Geiser et al., 2000). The microsclerotial strains differ from A. flavus and therefore it has been suggested that they represent a taxon separated from A. flavus (Geiser et al., 2000; Frisvad et al. 2005). Molecular phylogenetics suggests that SB isolates are closely related to the A. flavus type culture and other L strain isolates (Egel et al., 1994).

View larger version (124K): [in this window] [in a new window]   Fig. 1. Macroscopic features of A. flavus on Czapek's agar.

View larger version (143K): [in this window] [in a new window]   Fig. 2. Microscopic features of A. flavus.

	Molecular typing

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

Microsatellites are short tandemly repeated DNA sequences with a repetitive motif of 26 nt, forming tracts up to 100 nt long. Given the extensive polymorphism of microsatellites, they have proved to be epidemiologically useful for typing A. fumigatus (de Valk et al., 2005). Guarro et al. (2005) used random amplified microsatellites (RAMS) to type isolates of A. fumigatus and A. flavus obtained from a supposed outbreak. RAMS combines microsatellite and RAPD analysis. A discriminatory power of 0.9489 was obtained with the combination of two different primers. A full understanding of population(s) of A. flavus and the discriminatory power of these and other typing systems awaits a full population genetics study.

	Population genetics

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Two papers have demonstrated that agricultural isolates of A. flavus can be divided into two taxonomically distinct groups (Geiser et al., 1998, 2000). After analysing 314 Australian A. flavus isolates taken from agricultural soils, Geiser et al. (1998) found 16 different genotypes effectively forming two genetically distinct groups, namely I and II. All isolates of A. oryzae analysed appeared to be members of group I and almost no variation was observed amongst them. Isolates belonging to group II appeared to be more homogeneous than those in group I, implying clonal dissemination. It is unknown whether clinical isolates are members of only one or both groups. It is also unclear whether these taxonomic groupings have clinical significance in terms of mode of infection, drug resistance or virulence. The sequenced isolate NRRL 3357 aligns with group IC when the omt12 sequence is used in a phylogenetic alignment according to the parameters described by Geiser et al. (1998) (P. Bowyer, unpublished observations).

Although A. flavus is known to reproduce exclusively asexually in the laboratory, these populations are highly polymorphic in nature. In the phylogenetic study performed by Tran-Dihn et al. (1999) two distinct major profiles for the A. flavus isolates were observed by RAPD. In comparison to isolates belonging to the A. flavus group, RAPD profiles seemed to be considerably less variable within the groups of A. parasiticus isolates. Molecular typing of a larger global collection of A. flavus clinical isolates may contribute to a better understanding of whether there are differences in pathogenicity in the flavus complex. If we consider the fact that most of the outbreaks of A. flavus infection were caused by a single strain, it is possible that subspeciation and detailed population genetics in the flavus complex might be of great clinical relevance.

	Outbreaks

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Outbreaks of aspergillosis involving the skin, oral mucosa or subcutaneous tissues are more often associated with A. flavus than other species (Myoken et al., 2003; James et al., 2000; Heinemann et al., 2004; Vandecasteele et al., 2002; Allo et al., 1987; Grossman et al., 1985; Singer et al., 1998). This is quite distinct from what is observed for outbreaks caused by A. fumigatus, i.e. life-threatening pulmonary or sinuses diseases in severely immunocompromised patients. In fact, clusters of invasive sinusitis or invasive pulmonary infection caused purely by A. flavus are fairly unusual. In a recent review that aimed to summarize the data from all nosocomial Aspergillus outbreaks reported to date (Vonberg & Gastmeier, 2006), 53 outbreaks were found, affecting 458 patients. Species identified most often from clinical samples were A. fumigatus (n=154) and A. flavus (n=101). Although superficial skin infections occurred in only 24 patients (5.2 % of the total), A. flavus was reported in almost all of these cases where Aspergillus species were identified to the species level.

Another important difference between outbreaks of aspergillosis caused by A. fumigatus and A. flavus is the level of genetic diversity among outbreak isolates. Molecular studies have revealed that A. fumigatus isolates recovered from epidemics are usually genetically distinct, meaning that every patient tends to be infected by a different strain of A. fumigatus (Guarro et al., 2005). In contrast, most of the outbreaks caused by A. flavus have been associated with a single or a few different strains, indicating a point source outbreak (Myoken et al., 2003; James et al., 2000; Heinemann et al., 2004; Vandecasteele et al., 2002). There seems to be much less genetic diversity amongst clinical isolates of A. flavus in comparison with A. fumigatus.

	A. flavus as a mycotoxin producer

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Mycotoxins are fungal secondary metabolites that are potentially harmful to animals or humans. The word ‘aflatoxin’ came from ‘Aspergillus flavus toxin’, since A. flavus and A. parasiticus are the predominant species responsible for aflatoxin contamination of crops prior to harvest or during storage (Yu et al., 2004). The aflatoxins B1, B2, G1 and G2 are the major four toxins amongst at least 16 structurally related toxins (Goldblatt, 1969). Aflatoxin B1 is particularly important, since it is the most toxic and potent hepatocarcinogenic natural compound ever characterized (Bennett & Klich, 2003). Different A. flavus strains may or may not produce either aflatoxins B1 and/or B2. Other toxic compounds produced by A. flavus are sterigmatocystin, cyclopiazonic acid, kojic acid, β-nitropropionic acid, aspertoxin, aflatrem, gliotoxin and aspergillic acid (see http://www.aspergillus.org.uk – mycotoxin section). In addition A. flavus may produce some other secondary metabolites such as dihydroxyaflavinine, indole, paspalinine and versicolorin A (see http://www.aspergillus.org.uk – secondary metabolite section). A. parasiticus produces aflatoxin G1 and G2, in addition to B1 and B2, but not cyclopiazonic acid (Bennett & Klich, 2003; Yu, 2004). Aflatoxins are produced by some other species in Aspergillus flavus complex, including A. toxicarius, A. nomius, A. bombycis and A. pseudotamarii. A. pseudotamarii also produces cyclopiazonic acid. A. oryzae has long been used in the Orient to prepare various kinds of food products; it can produce cyclopiazonic acid and β-nitropropionic acid, but does not produce aflatoxin. A. oryzae, A. parasiticus, A. sojae, A. nomius, A. bombycis, A. tamarii, A. caelatus and A. pseudotamarii may produce kojic acid (Varga et al., 2003). Two sexually reproducing species in the Aspergillus flavus complex, P. alliaceus and P. albertensis, produce a high amount of ochratoxin A (50 300 mg ml^–1), and are considered to be responsible for ochratoxin A contamination of figs (Bayman et al., 2002).

	Pathogenicity

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
A. flavus has been studied in animal models for over 40 years but is still rarely used in comparison to A. fumigatus. Early studies of invasive aspergillosis in non-immunocompromised murine models demonstrated that A. flavus was more virulent than almost all other Aspergillus species, with only A. tamarii having marginally higher virulence (Ford & Friedman, 1967). More recently, studies in both normal and immunocompromised mice have demonstrated that LD₉₀ inocula for A. flavus are 100-fold lower than those required for A. fumigatus (Mosquera et al., 2001; Kamai et al., 2002). Following intravenous administration in non-neutropenic mice of A. flavus spores, the infection is rapidly concentrated in the liver and lungs within 4 h. The fungal burden in the lungs rapidly declines by 95 % over 24 h whilst the burden in the liver declines more slowly for 5 days following infection. In contrast, the burden in the kidneys and brain increases until a lethal burden develops 5–10 days post-infection (Ford & Friedman, 1967). The precise cause of death in mice with disseminated infection has not been characterized but tissue burdens immediately before death are much lower than occurs in A. fumigatus infections. It seems clear that aflatoxin is not a major factor in disease development, as strains which are unable to produce aflatoxin in vitro are similarly virulent (Richard et al., 1984); additionally, infections with aflatoxin-producing strains generate infections in which aflatoxin is undetectable in tissues (Richard et al., 1984).

Immunocompromised rats and rabbits have also been used as hosts of disseminated, invasive pulmonary and sinus A. flavus infections (Kaliamurthy et al., 2003). Infection results in death between 7 and 10 days post-infection, with the highest tissue burden recovered from the lungs>liver>brain>kidneys (this is in stark contrast to the tissue burdens in mice following A. fumigatus infection). Rabbits have been used as a model of paranasal sinus mycoses caused by A. flavus following direct injection into the sinus. In these studies the rabbits were not immunocompromised but required a very high inoculum (up to 10⁸ spores) to reliably establish an infection (Chakrabarti et al., 1997). Domestic chickens, geese and turkey poults are all susceptible to A. flavus without immunosuppression. Infections occur naturally in domestic flocks and can also be established following aerosol exposure.

	Human diseases

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
A. flavus causes a broad spectrum of disease in humans, ranging from hypersensitivity reactions to invasive infections associated with angioinvasion. After A. fumigatus, A. flavus is the second leading cause of invasive and non-invasive aspergillosis (Denning, 1998; Morgan et al., 2005). The primary route of infection is inhalation of fungal spores. The bigger size of A. flavus spores (25 µm in diameter in comparison to 23 µm for A. fumigatus) favours their deposition in the upper respiratory tract. Maybe this is one of the reasons why A. flavus is a common aetiological agent of fungal sinusitis and cutaneous infections, but not invasive fungal pneumonia. Possibly surface characteristics of the spores other than size are also important determinants of localization (Morrow, 1980).

As mentioned before, climate and geographical factors are important determinants of the local prevalence of A. flavus infections. In countries like Saudi Arabia and Sudan, with semi-arid and arid dry weather conditions, A. flavus is the main aetiological agent of invasive aspergillosis (Khairallah et al., 1992; Kameswaran et al., 1992). A. flavus is also one of the main pathogens responsible for pulmonary aspergillosis in Africa (Mahgoub & el-Hassan, 1972). For unknown reasons, the frequency of infections caused by A. flavus is also elevated in some hospitals, in different locales. Even though the clinical features of aspergillosis are generally identical for all of Aspergillus species, some particularities regarding A. flavus infections are described below.

Chronic cavitary pulmonary aspergillosis (CCPA) and aspergilloma
A. fumigatus causes the vast majority of cases of CCPA and aspergilloma (Denning et al., 2003). For unknown reasons, A. flavus has rarely been associated with CCPA (Liao et al., 1988; Staib et al., 1983). Approximately 10 cases have been reported so far, mostly from regions with hot and dry climate. Systemic oxalosis has mostly been associated with A. niger aspergillomas in diabetic patients, and it is rare with A. flavus (Dogan et al., 2004).

Allergic bronchopulmonary aspergillosis (ABPA) and allergens
Although A. fumigatus is responsible for the vast majority of ABPA cases, A. flavus has also been implicated in some series (Khan et al., 1976; Chakrabarti et al., 2002), mostly in studies from India. In addition, ABPA caused by Aspergillus flavus complex can also occur as an occupational disease. Many reports from Japan have shown that exposure to high concentrations of A. oryzae spores during the production of soybean products can lead to ABPA (Akiyama et al., 1987; Kurosawa et al., 1990). The vast majority of patients with ABPA have asthma; however, interestingly, some of these patients did not.

Several species of Aspergillus have been shown to be allergenic, including A. fumigatus, A. niger, A. flavus and A. oryzae. Over 20 allergens have been characterized in A. fumigatus, two from A. flavus (Asp fl 13 and Asp fl 18) and a further four from the closely related A. oryzae (Asp o 13, Asp o 21, Asp o lactase and Asp o lipase) (Mari & Riccioli, 2004; http://www.allergome.org/). Recent genome sequencing projects have made it possible to survey the allergens present in Aspergillus species. Table 2 shows predicted A. flavus allergen homologues by comparison with allergens from other Aspergillus species. It can be seen that many allergens present in A. fumigatus are present at high levels of homology in A. flavus. Proteins with >50 % identity to allergen proteins are likely to be immunologically cross-reactive (Bowyer et al., 2006). Asp o 21 and Asp o 13 allergens from the closely related A. oryzae are present at 98 and 100 % identity respectively and are likely to function as allergens in A. flavus. Additionally Asp f 1, Asp f 5, Asp f 12, Asp f 13, Asp f 18, Asp f 22 and Asp f 23 are all present in the A. flavus genome at >90 % identity and are likely to be allergenic in this species. Thus it is likely that A. flavus will produce many more allergenic proteins than the two currently known and may possess an allergen complement similar to that of A. fumigatus.

Cutaneous infection
Most cases of cutaneous aspergillosis are caused by A. flavus (van Burik et al., 1998; Chakrabarti et al., 1998). Skin involvement can be classified as either (i) primary, following direct inoculation of Aspergillus at sites of skin injury (e.g. intravenous catheter sites, traumatic inoculation, occlusive dressings, burns or surgery), or (ii) secondary, from haematogenous spread, most commonly following a pulmonary portal of entry, or from contiguous extension from a neighbouring cavity such as the maxillary sinus. The clinical presentation of cutaneous aspergillosis by A. flavus is characterized by the presence of violaceous macules, papules, plaques or nodules, haemorrhagic bullae, ulcerations with central necrosis with or without eschar formation, pustules or subcutaneous abscesses.

Wound infection
A. flavus is a particularly important species in wound aspergillosis, accounting for 41 % of cases confirmed by culture (Pasqualotto & Denning, 2006). Many studies have linked the occurrence of postoperative aspergillosis with the dissemination of Aspergillus spores in the operating room (Pasqualotto & Denning, 2006). Diaz-Guerra et al. (2000) reported the simultaneous isolation of one A. flavus isolate from the aortic prosthesis of a heart surgery patient, and another two isolates were recovered from a dual-reservoir cooler-heater used in the operating room where this patient was operated on. Genetic typing of these isolates by RAPD revealed identical genotypes, indicating the nosocomial origin of the strain. Aspergillus infection should always be considered in the differential diagnosis of slowly progressive but destructive wound infections, culture-negative pleural effusion and culture-negative mediastinitis after cardiac surgery.

Endocarditis and pericarditis
A. flavus has been reported as a cause of both native and prosthetic valve endocarditis, which is occasionally a manifestation of disseminated aspergillosis (Demaria et al., 2000; Rao & Saha, 2000; Irles et al., 2004). Occasional cases occur in patients with no overt risk factors (Kennedy et al., 1998; Khan et al., 1995). In postoperative Aspergillus endocarditis, A. flavus accounts for 11.2 % of cases (Pasqualotto & Denning, 2006). A rare case of fungal endocarditis (A. flavus) on a permanent pacemaker has been described (Acquati et al., 1987). Two reports have associated A. flavus with pericarditis (Cooper et al., 1981).

Central nervous system infection
Case series of craniocerebral aspergillosis due to A. flavus in immunocompetent hosts have been reported mainly from Pakistan, India, Saudi Arabia, Sudan and other African countries (Rudwan & Sheikh, 1976; Hussain et al., 1995; Panda et al., 1998). Most of these cases occurred as a complication of chronic granulomatous sinusitis, described below. These reports have speculated that tropical environmental conditions (hot and dry weather), bad hygiene and poor socioeconomic status are responsible (Rudwan & Sheikh, 1976; Hussain et al., 1995; Panda et al., 1998; Alrajhi et al., 2001).

Rhinosinusitis
A. flavus is more likely to be recovered from the upper respiratory tract than any other Aspergillus species (Chakrabarti et al., 1992; Hussain et al., 1995; Iwen et al., 1997; Kennedy et al., 1997; Panda et al., 1998). Clinical presentations of Aspergillus rhinosinusitis include acute and chronic invasive, chronic granulomatous and non-invasive syndromes (Hope et al., 2005). For an adequate diagnosis, tissue should be obtained for histopathology (fungal stains are essential), with fungal cultures of surgical specimens. Cultures of the nasal mucus are unreliable for diagnosis because the cultures reflect recent air sampling, rather than disease.

Chronic granulomatous sinusitis is a curious syndrome of chronic slowly progressive sinusitis associated with proptosis that has been also called indolent fungal sinusitis and primary paranasal granuloma. Florid granulomatous inflammation is the histological hallmark of this condition. Interestingly, almost all reports come from the Sudan (Milosev et al., 1969; Gumaa et al., 1992; Yagi et al., 1999), Saudi Arabia (Alrajhi et al., 2001) and the Indian subcontinent (Chakrabarti et al., 1992; Ramani et al., 1994; Panda et al., 2004). There are a limited number of reports in the USA, which appear to affect almost exclusively African-Americans (Currens et al., 2002). Whether this reflects climatic conditions and/or any genetic predisposition is unknown. Curiously, patients appear to be immunocompetent and are infected almost exclusively with A. flavus (Gumaa et al., 1992; Yagi et al., 1999; Alrajhi et al., 2001). Bone erosion is a common finding (Yagi et al., 1999) and tissue destruction occurs as a result of expansion of the mass rather than vascular invasion. Most individuals present with a unilateral proptosis (Milosev et al., 1969). Frequently there is direct spread beyond the confines of the sinuses to invade the brain, cavernous sinus, orbit and great vessels (Hope et al., 2005). Marked regression generally occurs following surgical procedures designed to produce adequate aeration of the sinuses. However, the recurrence rate is high (about 80 %), and some evidence suggests that the use of antifungal drugs may offer benefit (Gumaa et al., 1992).

Allergic fungal sinusitis (AFS) and sinus aspergilloma
Although A. fumigatus seems to be the most frequent Aspergillus organism causing AFS, A. flavus is particularly frequent in some geographical areas, such as the Middle East and India (Taj-Aldeen et al., 2003, 2004; Saravanan et al., 2006; Thakar et al., 2004). Patients with AFS may have co-existent mucosal granulomatous inflammation indicative of fungal tissue invasion (Thakar et al., 2004). In these cases from India, A. flavus was the only pathogen identified (Thakar et al., 2004). Sinus aspergilloma (fungus ball) is also usually caused by A. fumigatus and such infections caused by A. flavus are less frequent in developed countries (Milosev et al., 1969; Stammberger et al., 1984; Ferreiro et al., 1997). Again, A. flavus is more commonly isolated from patients in India, Sudan and other tropical countries (Panda et al., 1998; Yagi et al., 1999; Chakrabarti et al., 1992; Milosev et al., 1969).

Osteoarticular infection
A. flavus seems to be the main aetiological agent of Aspergillus osteomyelitis following trauma (Fisher, 1992), a situation which resembles the elevated frequency at which A. flavus causes primary cutaneous aspergillosis and wound infections.

Urinary tract infection
Urinary tract aspergillosis due to A. flavus is rare, with few cases reported (Khan et al., 1995; Perez-Arellano et al., 2001; Kueter et al., 2002). Usually a unilateral or bilateral fungal bezoar of the urinary pelvis is the presenting problem. Predisposing conditions include diabetes, intravenous drug addiction and schistosomiasis.

	Resistance to antifungal drugs

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Until recent years, the only drugs available to treat aspergillosis were amphotericin B (AmB) and itraconazole, the latter in oral and intravenous formulations. Recently voriconazole, posaconazole and caspofungin have also been approved for the treatment of aspergillosis. Although resistance to antifungal drugs is not as great a concern as resistance to antibacterial agents, there has been an increase in the number of reported cases of both primary and secondary resistance in human mycoses (Denning et al., 1997). Therefore, it seems possible that resistance of the fungus to the drug or an inadequate concentration of the antifungal drug at the site of infection might contribute to the high mortality rate seen for these infections.

Amphotericin B
Although the true rate of AmB resistance is unknown, some investigators have reported isolates of A. flavus resistant to AmB in vitro (Odds et al., 1998; Lass-Florl et al., 1998; Seo et al., 1999; Mosquera et al., 2001; Gomez-Lopez et al., 2003; Sutton et al., 2004; Hsueh et al., 2005), although this is not universally accepted. In a study from Taiwan (Hsueh et al., 2005) isolates of A. flavus and A. fumigatus with reduced susceptibilities to AmB were found (MICs 2 µg ml^–1). Among the four species tested, A. flavus was the least susceptible to AmB; the MICs at which 50 % and 90 % of A. flavus isolates were inhibited were twofold greater than those for A. fumigatus and A. niger.

A preliminary report has documented a steady increase in AmB resistance in vitro amongst Aspergillus isolates recovered since 2001 (Sutton et al., 2004). About 20 % of A. fumigatus and A. flavus isolates recovered in 2004 had minimum lethal concentrations (MLCs) of AmB 16 µg ml^–1 compared to 0 % in 2001. Some investigators have hypothesized that the extensive use of AmB against fungal infections has led to the emergence of less susceptible species, such as A. terreus and A. flavus (Marr et al., 2002). Recently, Lionakis et al. (2005) found that the proportion of Aspergillus spp. resistant to antifungals (especially AmB) was much higher amongst isolates recovered from cancer patients with prior exposure to AmB or triazoles.

Few data are available regarding correlations between MIC and outcome of treatment with AmB for infections caused by Aspergillus species. In the survey of Odds et al. (1998) the efficacy of AmB at 0.31 mg kg^–1 was seen in vivo against A. fumigatus (MIC 1 µg ml^–1) but efficacy was not seen against A. flavus at the same MIC, at any dose tested. In another study (Lass-Florl et al., 1998), AmB MICs of 2 µg ml^–1 were associated with treatment failure amongst patients with invasive aspergillosis. Mosquera et al. (2001) demonstrated a lack of correlation between susceptibility to AmB in vitro and clinical outcome for A. flavus infections in vivo by using different susceptibility testing methods, including the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) M-38A method. Difficulty in treating invasive aspergillosis might relate in part to poor penetration of AmB into infected tissue (Paterson et al., 2003).

Itraconazole
Itraconazole resistance in Aspergillus species is presumptively defined as an MIC of 8 µg ml^–1 (Gomez-Lopez et al., 2003). According to this criterion, Hsueh et al. (2005) found resistance to itraconazole in 4.2 % (4 of 96) of Aspergillus species, including two A. fumigatus and two A. flavus isolates. Similar rates of resistance were found amongst isolates included in previous studies (Gomez-Lopez et al., 2003; Lionakis et al., 2005). In the study by Hsueh et al. (2005), all of the Aspergillus isolates tested were inhibited by 8 µg itraconazole ml^–1. Recently, Lionakis et al. (2005) showed that 11 % of the A. flavus isolates in their study were itraconazole resistant based on in vitro susceptibility by tests performed by the CLSI method; using the E-test, only 6 % of A. flavus isolates could be classified as itraconazole resistant. Again, in vitro susceptibility test results may not reflect in vivo response, as demonstrated by Mosquera et al. (2001).

Voriconazole
Voriconazole has good in vitro activity against a range of Aspergillus species, including A. flavus (Pfaller et al. 2002; Diekema et al., 2003; Lass-Florl et al., 2001). Hsueh et al. (2005) showed that all of the Aspergillus isolates tested, including A. flavus, were inhibited by 1 µg voriconazole ml^–1. Voriconazole MICs are slightly higher than those of itraconazole for A. flavus (Maesaki et al., 2000; Gomez-Lopez et al., 2003). The precise inoculum used can alter the MIC, so higher inocula yield higher and potentially resistant end points (Mosquera et al., 2001). Discordance in results with the CLSI and E-test methods with voriconazole is problematic (Lionakis et al., 2005). Since validated methodology and breakpoints for voriconazole have not yet been established, the rate of resistance is not known. However, some Aspergillus isolates seem to show cross-resistance to itraconazole and voriconazole, as demonstrated with A. fumigatus, and this is strain (and presumably mechanism) dependent (Espinel-Ingroff et al., 2001; Pfaller et al., 2002).

Other antifungal agents
Caspofungin, anidulafungin and micafungin are members of the echinocandin group of antifungal agents that target 1,3-β-glucan synthase, disrupting hyphal growth at tips and branch points. Caspofungin and micafungin are available for the treatment of invasive aspergillosis and hold promise for treatment alone or in combination with triazoles or AmB (Marr et al., 2002; Cesaro et al., 2004). A. flavus would appear to be slightly less susceptible than A. fumigatus to echinocandins, based on in vitro parameters (Oakley et al., 1998; Espinel-Ingroff, 2003) but eradication rates were 20–25 % better for A. flavus infection than A. fumigatus in two salvage studies (Maertens et al., 2004; Denning et al., 2006). Thus a species difference in susceptibility to echinocandins may exist, but is not obviously clinically relevant, and could reflect the difficulties in interpretation of in vitro results with echinocandins. No isolates of A. flavus have yet been described that are resistant to posaconazole.

	Conclusions

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
A. flavus is the second most important Aspergillus species causing human infections. The importance of this fungus increases in regions with a dry and hot climate. In addition, many A. flavus isolates produce aflatoxin B1, the most toxic and potent hepatocarcinogenic natural compound ever characterized. Small studies of phylogenetic species in A. flavus indicate that the morphological species contains several genetically isolated species, and until a population-based discriminatory molecular typing system is applied, we will not know the full extent of diversity in A. flavus, sensu lato. Population genetics studies on isolates causing disease would be of great interest. Particularly common clinical syndromes associated with A. flavus include chronic granulomatous sinusitis, keratitis, cutaneous aspergillosis, wound infections and osteomyelitis following trauma and inoculation. On the other hand, A. flavus is rarely the aetiological agent of chronic cavitary pulmonary aspergillosis. In frank contrast to A. fumigatus infections, most of the investigated outbreaks caused by A. flavus were due to a single or a few strains, assuming that the typing systems used were sufficiently discriminatory. Finally, A. flavus seems to be more virulent and more resistant to antifungal drugs than most of the other Aspergillus species. Hopefully, recently published information about the Aspergillus genomes will help us to better understand the pathogenesis of these infections, as well as providing insights into toxin production and allergens.

	ACKNOWLEDGEMENTS

 
Dr Pasqualotto receives a grant from CAPES (Brazilian government). Peter Warn is supported by the Fungal Research Trust and NIAID contract no. N01-AI-30041 ‘Invasive Aspergillosis Animal Models’.

	REFERENCES

TOP ABSTRACT Introduction Ecology and geographical... Genome Taxonomy Identification Molecular typing Population genetics Outbreaks A. flavus as a... Pathogenicity Human diseases Resistance to antifungal drugs Conclusions REFERENCES

 
Abdalla, M. H. (1988). Prevalence of airborne Aspergillus flavus in Khartoum (Sudan) airspora with reference to dusty weather and inoculum survival in simulated summer conditions. Mycopathologia 104, 137–141.[CrossRef][Medline]

Acquati, F., Semeraro, F., Respighi, E., Gallotti, R., Repetto, S. & Binaghi, G. (1987). Aspergillus flavus-infection of a pacemaker wire: continuing evidence for active management of infected pacemakers. G Ital Cardiol 17, 467–468.[Medline]

Adhikari, A., Sen, M. M., Gupta-Bhattacharya, S. & Chanda, S. (2004). Airborne viable, non-viable, and allergenic fungi in a rural agricultural area of India: a 2-year study at five outdoor sampling stations. Sci Total Environ 326, 123–141.[CrossRef][Medline]

Akiyama, K., Takizawa, H., Suzuki, M., Miyachi, S., Ichinohe, M. & Yanagihara, Y. (1987). Allergic bronchopulmonary aspergillosis due to Aspergillus oryzae. Chest 91, 285–286.[CrossRef][Medline]

Allo, M. D., Miller, J., Townsend, T. & Tan, C. (1987). Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 317, 1105–1108.[Abstract]

Alrajhi, A. A., Enani, M., Mahasin, Z. & Al-Omran, K. (2001). Chronic invasive aspergillosis of the paranasal sinuses in immunocompetent hosts from Saudi Arabia. Am J Trop Med Hyg 65, 83–86.[Abstract]

Anaissie, E. J., Stratton, S. L., Dignani, M. C., Summerbell, R. C., Rex, J. H., Monson, T. P., Spencer, T., Kasai, M., Francesconi, A. & Walsh, T. J. (2002). Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 34, 780–789.[CrossRef][Medline]

Bartoli, A. & Maggi, O. (1978). Four new species of Aspergillus from Ivory Coast Soil. Trans Br Mycol Soc 71, 383–394.

Batista, A. C. & da Silva Maia, H. M. (1955). Aspergillus flavo-furcatis. An Soc Biol Pernamb 8, 94–96.

Bayman, P., Baker, J. L., Doster, M. A., Michailides, T. J. & Mahoney, N. E. (2002). Ochratoxin production by the Aspergillus ochraceus group and Aspergillus alliaceus. Appl Environ Microbiol 68, 2326–2329.[Abstract/Free Full Text]

Bennett, J. W. & Klich, M. (2003). Mycotoxins. Clin Microbiol Rev 16, 497–516.[Abstract/Free Full Text]

Bhatnagar, D., Cleveland, T. E. & Payne, G. A. (2000). Encyclopedia of Food Microbiology, pp. 72–79. London: Academic Press.

Bowyer, P., Fraczek, M. & Denning, D. W. (2006). Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. BMC Genomics 7, 251[CrossRef][Medline]

Bruns, T. D., White, T. J. & Taylor, J. W. (1991). Fungal molecular systematics. Annu Rev Ecol Syst 22, 525–564.[CrossRef]

Buffington, J., Reporter, R., Lasker, B. A., McNeil, M. M., Lanson, J. M., Ross, L. A., Mascola, L. & Jarvis, W. R. (1994). Investigation of an epidemic of invasive aspergillosis: utility of molecular typing with the use of random amplified polymorphic DNA probes. Pediatr Infect Dis J 13, 386–393.[Medline]

Calvo, A., Guarro, J., Suarez, G. & Ramirez, C. (1980). Air-borne fungi in the air of Barcelona (Spain). III. The genus Aspergillus Link. Mycopathologia 71, 41–43.[CrossRef][Medline]

Cameron, J. A., Antonios, S. R., Cotter, J. B. & Habash, N. R. (1991). Endophthalmitis from contaminated donor corneas following penetrating keratoplasty. Arch Ophthalmol 109, 54–59.[Abstract/Free Full Text]

Campbell, C. K. (1994). Forms of aspergillosis. In The Genus Aspergillus, pp. 313–320, Edited by K. A. Powell, A. Renwick & J. F. Peberdy. New York: Plenum.

Cesaro, S., Toffolutti, T., Messina, C., Calore, E., Alaggio, R., Cusinato, R., Pillon, M. & Zanesco, L. (2004). Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 73, 50–55.[CrossRef][Medline]

Chakrabarti, A., Sharma, S. C. & Chandler, J. (1992). Epidemiology and pathogenesis of paranasal sinus mycoses. Otolaryngol Head Neck Surg 107, 745–750.[Medline]

Chakrabarti, A., Jatana, M. & Sharma, S. C. (1997). Rabbit as an animal model of paranasal sinus mycoses. J Med Vet Mycol 35, 295–297.[Medline]

Chakrabarti, A., Gupta, V., Biswas, G., Kumar, B. & Sakhuja, V. K. (1998). Primary cutaneous aspergillosis: our experience in 10 years. J Infect 37, 24–27.[Medline]

Chakrabarti, A., Sethi, S., Raman, D. S. & Behera, D. (2002). Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses 45, 295–299.[CrossRef][Medline]

Cheikh-Rouhou, F., Makni, F., Ayadi, A., Ghorbel, R. & Ben Zina, Z. (2001). Ocular parasitoses and mycoses: cases diagnosed in the Central University Hospital of Sfax between 1996 and 1999. Bull Soc Pathol Exot 94, 11–13.[Medline]

Christensen, M. & Raper, K. B. (1978). Aspergillus robustus, a new species in the A. ochraceus group. Mycologia 70, 200–205.[CrossRef]

Cohn, A. (1883). Aspergillus oryzae. Jahresber Schles Ges Vaterl Kultur 61, 226

Cooper, J. A., Weinbaum, D. L., Aldrich, T. K. & Mandell, G. L. (1981). Invasive aspergillosis of the lung and pericardium in a nonimmunocompromised 33 year old man. Am J Med 71, 903–907.[CrossRef][Medline]

Cotty, P. (1989). Virulence and cultural characteristics of two Aspergillus flavus strains pathogenic on cotton. Phytopathology 79, 808–814.[CrossRef]

Currens, J., Hutcheson, P. S., Slavin, R. G. & Citardi, M. J. (2002). Primary paranasal Aspergillus granuloma: case report and review of the literature. Am J Rhinol 16, 165–168.[Medline]

de Valk, H. A., Meis, J. F., Curfs, I. M., Muehlethaler, K., Mouton, J. W. & Klaassen, C. H. (2005). Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol 43, 4112–4120.[Abstract/Free Full Text]

Demaria, R. G., Durrleman, N., Rispail, P., Margueritte, G., Macia, J. C., Aymard, T., Frapier, J. M., Albat, B. & Chaptal, P. A. (2000). Aspergillus flavus mitral valve endocarditis after lung abscess. J Heart Valve Dis 9, 786–790.[Medline]

Demicco, D. D., Reichman, R. C., Violette, E. J. & Winn, W. C., Jr (1984). Disseminated aspergillosis presenting with endophthalmitis. A case report and a review of the literature. Cancer 53, 1995–2001.[CrossRef][Medline]

Denning, D. W. (1998). Invasive aspergillosis. Clin Infect Dis 26, 781–803.[Medline]

Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W. & Kelly, S. L. (1997). Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41, 1364–1368.[Abstract]

Denning, D. W., Riniotis, K., Dobrashian, R. & Sambatakou, H. (2003). Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature and review. Clin Infect Dis 37, S265–S280.[CrossRef][Medline]

Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M. & other authors (2006). Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53, 337–349.[CrossRef][Medline]

Diaz-Guerra, T. M., Mellado, E., Cuenca-Estrella, M., Gaztelurrutia, L., Navarro, J. I. V. & Tudela, J. L. R. (2000). Genetic similarity among one Aspergillus flavus strain isolated from a patient who underwent heart surgery and two environmental strains obtained from the operating room. J Clin Microbiol 38, 2419–2422.[Abstract/Free Full Text]

Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N. & Pfaller, M. A. (2003). Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41, 3623–3626.[Abstract/Free Full Text]

Dogan, M., Pabuccuoglu, U., Sarioglu, S. & Yucesoy, M. (2004). Isolated nasopharyngeal aspergillosis caused by A. flavus and associated with oxalosis. Ear Nose Throat J 83, 331–333.[Medline]

Egel, D. S., Cotty, P. J. & Elias, K. S. (1994). Relationships among isolates of Aspergillus sect. Flavi that vary in aflatoxin production. Phytopathology 84, 906–912.[CrossRef]

Espinel-Ingroff, A. (2003). Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 41, 403–409.[Abstract/Free Full Text]

Espinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M. & Walsh, T. J., NCCLS (2001). Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: National Committee for Clinical Laboratory Standards collaborative evaluation. Antimicrob Agents Chemother 45, 1828–1835.[Abstract/Free Full Text]

Ferreiro, J. A., Carlson, B. A. & Cody, D. T. 3rd (1997). Paranasal sinus fungus balls. Head Neck 19, 481–486.[CrossRef][Medline]

Fisher, M. S. (1992). Case report 750: Aspergillosis of the chest wall in an apparently immunocompetent host. Skeletal Radiol 21, 410–413.[Medline]

Ford, S. & Friedman, L. (1967). Experimental study of the pathogenicity of aspergilli for mice. J Bacteriol 94, 928–933.[Abstract/Free Full Text]

Frisvad, J. C., Skouboe, P. & Samson, R. A. (2005). Taxonomic comparison of three different groups of aflatoxin producers and a new efficient producer of aflatoxin B1, sterigmatocystin and 3-O-methylsterigmatocystin, Aspergillus rambellii sp. nov. Syst Appl Microbiol 28, 442–453.[CrossRef][Medline]

Galagan, J. E., Calvo, S. E., Cuomo, C., Ma, L. J., Wortman, J. R., Batzoglou, S., Lee, S. I., Basturkmen, M., Spevak, C. C. & other authors (2005). Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature 438, 1105–1115.[CrossRef][Medline]

Geiser, D. M., Pitt, J. I. & Taylor, J. W. (1998). Cryptic speciation and recombination in the aflatoxin-producing fungus Aspergillus flavus. Proc Natl Acad Sci U S A 95, 388–393.[Abstract/Free Full Text]

Geiser, D. M., Dorner, J. W., Horn, B. W. & Taylor, J. W. (2000). The phylogenetics of mycotoxin and sclerotium production in Aspergillus flavus and Aspergillus oryzae. Fungal Genet Biol 31, 169–179.[CrossRef][Medline]

Gibson, A. M., Baranyi, J., Pitt, M. J., Eyles, M. J. & Roberts, T. A. (1994). Predicting fungal growth: the effect of water activity on Aspergillus flavus and related species. Int J Food Microbiol 23, 419–431.[CrossRef][Medline]

Goldblatt, L. A. (1969). Aflatoxin – Scientific Background, Control and Implications. New York: Acaderitic Press.

Gomez-Lopez, A., Garcia-Effron, G., Mellado, E., Monzon, A., Rodriguez-Tudela, J. L. & Cuenca-Estrella, M. (2003). In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 47, 3085–3088.[Abstract/Free Full Text]

Goncalves, A. B., Paterson, R. R. & Lima, N. (2006). Survey and significance of filamentous fungi from tap water. Int J Hyg Environ Health 209, 257–264.[CrossRef][Medline]

Gottlich, E., Van der Lubbe, W., Lange, B., Fiedler, S., Melchert, I., Reifenrath, M., Flemming, H. C. & de Hoog, S. (2002). Fungal flora in groundwater-derived public drinking water. Int J Hyg Environ Health 205, 269–279.[CrossRef][Medline]

Grossman, M. E., Fithian, E. C., Behrens, C., Bissinger, J., Fracaro, M. & Neu, H. C. (1985). Primary cutaneous aspergillosis in six leukemic children. J Am Acad Dermatol 12, 313–318.[Medline]

Guarro, J., Sole, M., Castany, R., Cano, J., Teixido, A., Pujol, I., Gene, J., Castro, A. & Sarda, P. (2005). Use of random amplified microsatellites to type isolates from an outbreak of nosocomial aspergillosis in a general medical ward. Med Mycol 43, 365–371.[Medline]

Gugnani, H. C., Gupta, S. & Talwar, R. S. (1978). Role of opportunistic fungi in ocular infections in Nigeria. Mycopathologia 65, 155–166.[CrossRef][Medline]

Guinea, J., Peláez, T., Alcalá, L. & Bouza, E. (2005). Evaluation of Czapeck agar and Sabouraud dextrose agar for the culture of airborne Aspergillus conidia. Diagn Microbiol Infect Dis 53, 333–334.[CrossRef][Medline]

Gumaa, S. A., Mahgoub, E. S. & Hay, R. J. (1992). Post-operative responses of paranasal Aspergillus granuloma to itraconazole. Trans R Soc Trop Med Hyg 86, 93–94.[CrossRef][Medline]

Gupta, S. K., Pereira, B. M. & Singh, A. B. (1993). Survey of airborne culturable and non-culturable fungi at different sites in Delhi metropolis. Asian Pac J Allergy Immunol 11, 19–28.[Medline]

Hedayati, M. T., Mayahi, S., Aghil, R. & Goharimoghadam, K. (2005). Airborne fungi in indoor and outdoor of asthmatic patients' home, living in the city of Sari. Iran J Allergy Asthma Immunol 4, 189–191.[Medline]

Heinemann, S., Symoens, F., Gordts, B., Jannes, H. & Nolard, N. (2004). Environmental investigations and molecular typing of Aspergillus flavus during an outbreak of postoperative infections. J Hosp Infect 57, 149–155.[CrossRef][Medline]

Hope, W. W., Walsh, T. J. & Denning, D. W. (2005). The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43 (Suppl. 1), S207–S238.[CrossRef][Medline]

Horn, B. (1997). Aspergillus caelatus, a new species in section Flavi. Mycotaxon 56, 185–191.

Hsueh, P. R., Lau, Y. J., Chuang, Y. C., Wan, J. H., Huang, W. K., Shyr, J. M., Yan, J. J., Yu, K. W., Jiunn-Jong Wu, J. J. & other authors (2005). Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan Program Data from 2003. Antimicrob Agents Chemother 49, 512–517.[Abstract/Free Full Text]

Hussain, S., Salahuddin, N., Ahmad, I., Salahuddin, I. & Jooma, R. (1995). Rhinocerebral invasive mycosis: occurrence in immunocompetent individuals. Eur J Radiol 20, 151–155.[CrossRef][Medline]

Irles, D., Bonadona, A., Pofelski, J., Laramas, M., Molina, L., Lantuejoul, S., Brenier-Pinchart, M. P., Bagueta, J. P. & Barnoud, D. (2004). Aspergillus flavus endocarditis on a native valve. Arch Mal Coeur Vaiss 97, 172–175.[Medline]

Ito, Y., Peterson, S. W., Wicklow, D. T. & Goto, T. (2001). Aspergillus pseudotamarii, a new aflatoxin producing species in Aspergillus section Flavi. Mycol Res 105, 233–239.[CrossRef]

Iwen, P. C., Rupp, M. E. & Hinrichs, S. H. (1997). Invasive mold sinusitis: 17 cases in immunocompromised patients and review of the literature. Clin Infect Dis 24, 1178–1184.[Medline]

James, M. J., Lasker, B. A., McNeil, M. M., Shelton, M., Warnock, D. W. & Reiss, E. (2000). Use of a repetitive DNA probe to type clinical and environmental isolates of Aspergillus flavus from a cluster of cutaneous infections in a neonatal intensive care unit. J Clin Microbiol 38, 3612–3618.[Abstract/Free Full Text]

Kaliamurthy, J., Geraldine, J. P. & Thomas, P. A. (2003). Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy. Mycoses 46, 174–182.[CrossRef][Medline]

Kamai, Y., Harasaki, T., Fukuoka, T., Ohya, S., Uchida, K., Yamaguchi, H. & Kuwahara, S. (2002). In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob Agents Chemother 46, 367–370.[Abstract/Free Full Text]

Kamal & Bhargava, K. S. (1969). Aspergillus lanosus. Trans Br Mycol Soc 52, 336

Kameswaran, M., al-Wadei, A., Khurana, P. & Okafor, B. C. (1992). Rhinocerebral aspergillosis. J Laryngol Otol 106, 981–985.[Medline]

Kennedy, C. A., Adams, G. L., Neglia, J. P. & Giebink, G. S. (1997). Impact of surgical treatment on paranasal fungal infections in bone marrow transplant patients. Otolaryngol Head Neck Surg 116, 610–616.[CrossRef][Medline]

Kennedy, H. F., Simpson, E. M., Wilson, N., Richardson, M. D. & Michie, J. R. (1998). Aspergillus flavus endocarditis in a child with neuroblastoma. J Infect 36, 126–127.[CrossRef][Medline]

Khairallah, S. H., Byrne, K. A. & Tabbara, K. F. (1992). Fungal keratitis in Saudi Arabia. Doc Ophthalmol 79, 269–276.[CrossRef][Medline]

Khan, Z. U., Sandhu, R. S., Randhawa, H. S., Menon, M. P. & Dusaj, I. S. (1976). Allergic bronchopulmonary aspergillosis: a study of 46 cases with special reference to laboratory aspects. Scand J Respir Dis 57, 73–87.[Medline]

Khan, Z. U., Gopalakrishnan, G., Al-Awadi, K., Gupta, R. K., Moussa, S. A., Chugh, T. D. & Krajci, D. (1995). Renal aspergilloma due to Aspergillus flavus. Clin Infect Dis 21, 210–212.[Medline]

Kita (1913). Aspergillus tamarii. Centbl Bakt Parasit Kde Abt 37, 433–452.

Klich, M. A. & Mullaney, E. J. (1987). DNA restriction enzyme fragment length polymorphism as a tool for differentiation of Aspergillus flavus and Aspergillus oryzae. Exp Mycol 11, 170–175.[CrossRef]

Klich, M. A. & Pitt, J. L. (1988). Differentiation of Aspergillus flavus from A. parasiticus and other closely related species. Trans Br Mycol Soc 91, 99–108.

Kozakiewicz, Z. (1989). Aspergillus Species on Stored Products. Wallingford: CAB International.

Kueter, J. C., MacDiarmid, S. A. & Redman, J. F. (2002). Anuria due to bilateral ureteral obstruction by Aspergillus flavus in an adult male. Urology 59, 601[Medline]

Kumeda, Y. & Asao, T. (1996). Single-strand conformation polymorphism analysis of PCR-amplified ribosomal DNA internal transcribed spacers to differentiate species of Aspergillus section Flavi. Appl Environ Microbiol 62, 2947–2952.[Abstract]

Kurosawa, M., Kobayashi, S., Yanagihara, Y. & Shida, T. (1990). A case of occupational allergic bronchopulmonary aspergillosis unique to Japan. Br J Clin Pract 44, 482–489.[Medline]

Kurtzman, C. P., Smiley, M. J., Robnett, C. J. & Wicklow, D. T. (1986). DNA relatedness among wild and domesticated species in the Aspergillus flavus group. Mycologia 78, 955–959.[CrossRef]

Kurtzman, C. P., Horn, B. W. & Hesseltine, C. W. (1987). Aspergillus nomius, a new aflatoxin-producing species related to Aspergillus flavus and Aspergillus tamarii. Antonie van Leeuwenhoek 53, 147–158.[CrossRef][Medline]

Lance, S. E., Friberg, T. R. & Kowalski, R. P. (1988). Aspergillus flavus endophthalmitis and retinitis in an intravenous drug abuser. A therapeutic success. Ophthalmology 95, 947–949.[Medline]

Lass-Florl, C., Kofler, G., Kropshofer, G., Hermans, J., Kreczy, A., Dierich, M. P. & Niederwieser, D. (1998). In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 42, 497–502.[Abstract/Free Full Text]

Lass-Florl, C., Nagl, M., Speth, C., Ulmer, H., Dierich, M. P. & Würzner, R. (2001). Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 45, 124–128.[Abstract/Free Full Text]

Li, D. M., Horie, Y., Wang, Y. & Li, R. (1998). Three new Aspergillus species isolated from clinical sources as a causal agent of human aspergillosis. Mycoscience 39, 299–305.[CrossRef]

Liao, W. Q., Shao, J. Z., Li, S. Q., Wan, G. T., Da, Z. W., Sun, Y. C., Qi, Z. T., Chen, Q. T. & Sun, Z. M. (1988). Mycological identification of pulmonary aspergilloma caused by Aspergillus oryzae with proliferating heads. Chin Med J (Engl) 101, 601–604.[Medline]

Link, H.F. (1809). Observationes in Ordines plantarum naturales. Dissertatio prima, complectens Anandrarum ordines Epiphytas, Mucedines Gastomycos et Fungos Der Gesellschaft Naturforschender Freunde zu Berlin. Magazin für die neuesten Entdeckungen in der gesamten Naturkunde 3, 1–42.

Lionakis, M. S., Lewisa, R. L., Torresa, H. A., Alberta, N. D., Raada, I. I. & Kontoyiannisa, D. P. (2005). Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 52, 15–20.[CrossRef][Medline]

Machida, M., Asai, K., Sano, M., Tanaka, T., Kumagai, T., Terai, G., Kusumoto, K., Arima, T., Akita, O. & other authors (2005). Genome sequencing and analysis of Aspergillus oryzae. Nature 438, 1157–1161.[CrossRef][Medline]

Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A. & other authors (2004). Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39, 1563–1571.[CrossRef][Medline]

Maesaki, S., Iwakawa, J., Higashiyama, Y., Miyazaki, Y., Yanagihara, K., Tomono, K., Tashiro, T. & Kohno, S. (2000). Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother 6, 101–103.[CrossRef][Medline]

Mahgoub, E. S. & el-Hassan, A. M. (1972). Pulmonary aspergillosis caused by Aspergillus flavus. Thorax 27, 33–37.[Abstract/Free Full Text]

Mallea, M., Murray, I. G., Segretain, G., Philpot, C. M., Charpin, H., Gueho, E. & Charpin, J. (1972). Census of Aspergillus colonies in the air comparison between London, Paris, Lyon, Marseilles. Acta Allergol 27, 273–278.[Medline]

Marchal, É. J. (1893). Aspergillus terricola. Rev Mycol (Toulouse) 15, 101

Mari, A. & Riccioli, D. (2004). The Allergome Web Site – a database of allergenic molecules. Aim, structure, and data of a web-based resource. 60th Annual Meeting American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 113, S301

Marr, K. A., Carter, R. A., Crippa, F., Wald, A. & Corey, L. (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34, 909–917.[CrossRef][Medline]

Mehrotra, B. S. & Agnihotri, V. P. (1962). Aspergillus indicus. Mycologia 54, 403

Mendicute, J., Orbegozo, J., Ruiz, M., Saiz, A., Eder, F. & Aramberri, J. (2000). Keratomycosis after cataract surgery. J Cataract Refract Surg 26, 1660–1666.[CrossRef][Medline]

Milosev, B., el-Mahgoub, S., Aal, O. A. & el-Hassan, A. M. (1969). Primary aspergilloma of paranasal sinuses in the Sudan. A review of seventeen cases. Br J Surg 56, 132–137.[Medline]

Montiel, D., Dickinson, M. J., Lee, H. A., Dyer, P. S., Jeenes, D. J., Roberts, I. N., James, S., Fuller, L. J., Matsuchima, K. & Archer, D. B. (2003). Genetic differentiation of the Aspergillus section Flavi complex using AFLP fingerprints. Mycol Res 107, 1427–1434.[CrossRef][Medline]

Moody, S. F. & Tyler, B. M. (1990). Restriction enzyme analysis of mitochondrial DNA of the Aspergillus flavus group: A. flavus, A. parasiticus, and A. nomius. Appl Environ Microbiol 56, 2441–2452.[Abstract/Free Full Text]

Morgan, J., Wannemuehler, K. A., Marr, K. A., Hadley, S., Kontoyiannis, D. P., Walsh, T. J., Fridkin, S. K., Pappas, P. G. & Warnock, D. W. (2005). Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 (Suppl. 1), S49–S58.[CrossRef][Medline]

Morrow, P. E. (1980). Physics of airborne particles and their deposition in the lung. Ann N Y Acad Sci 353, 71–80.[Medline]

Mosquera, J., Warn, P. A., Morrissey, J., Moore, C. B., Gil-Lamaignere, C. & Denning, D. W. (2001). Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 45, 1456–1462.[Abstract/Free Full Text]

Moubasher, A. H., Abdel-Fattah, H. M. & Swelim, M. A. (1981). Studies on air-borne fungi at Qena. I. Seasonal fluctuations. Z Allg Mikrobiol 21, 247–253.[CrossRef][Medline]

Murakami, H. (1971). Classification of the Koji mold. J Gen Appl Microbiol 17, 281–309.[CrossRef]

Myoken, Y., Sugata, T., Fujita, Y., Kyo, T., Fujihara, M., Kohara, T., Katsu, M. & Mikami, Y. (2003). Molecular epidemiology of invasive stomatitis due to Aspergillus flavus in patients with acute leukemia. J Oral Pathol Med 32, 215–218.[Medline]

Niemi, R. M., Knuth, S. & Lundstrom, K. (1982). Actinomycetes and fungi in surface waters and in potable water. Appl Environ Microbiol 43, 378–388.[Abstract/Free Full Text]

Nozawa, K., Sekita, S., Harada, M., Udagawa, S. & Kawai, K. (1989). Isolation and structures of two new indoloterpenes related to aflavine from a microsclerotium-producing strain of Aspergillus flavus. Chem Pharm Bull (Tokyo) 37, 626–630.

Oakley, K. L., Moore, C. B. & Denning, D. W. (1998). In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 42, 2726–2730.[Abstract/Free Full Text]

Odds, F. C., Gerven, F. V., Espinel-Ingroff, A., Bartlett, M. S., Ghannoum, M. A., Lancaster, M. V., Pfaller, M. A., Rex, J. H., Rinaldi, M. G. & Walsh, T. J. (1998). Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 42, 282–288.[Abstract/Free Full Text]

Panda, N. K., Sharma, S. C., Chakrabarti, A. & Mann, S. B. (1998). Paranasal sinus mycoses in north India. Mycoses 41, 281–286.[Medline]

Panda, N. K., Balaji, P., Chakrabarti, A., Sharma, S. C. & Reddy, C. E. (2004). Paranasal sinus aspergillosis: its categorization to develop a treatment protocol. Mycoses 47, 277–283.[CrossRef][Medline]

Pasqualotto, A. C. & Denning, D. W. (2006). Post-operative aspergillosis. Clin Microbiol Infect 12, 1060–1076.[CrossRef][Medline]

Paterson, R. R., Kelley, J. & Gallagher, M. (1997). Natural occurrence of aflatoxins and Aspergillus flavus (Link) in water. Lett Appl Microbiol 25, 435–436.[CrossRef][Medline]

Paterson, P. J., Seaton, S., Prentice, H. G. & Kibbler, C. C. (2003). Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 52, 873–876.[Abstract/Free Full Text]

Perez-Arellano, J. L., Angel-Moreno, A., Belon, E., Frances, A., Santana, O. E. & Martin-Sanchez, A. M. (2001). Isolated renoureteric aspergilloma due to Aspergillus flavus: case report and review of the literature. J Infect 42, 163–165.[CrossRef][Medline]

Peterson, S. W. (2000). Phylogenetic relationships in Aspergillus based on rDNA sequence analysis. In Integration of Modern Taxonomic Methods for Penicillium and Aspergillus Classification, pp. 323–355, edited by R. A. Samson & J. I. Pitt. Amsterdam: Harwood Academic Publishers.

Peterson, S. W., Ito, Y., Horn, B. W. & Goto, T. (2001). Aspergillus bombycis, a new aflatoxigenic species and genetic variation in its sibling species, A. nomius. Mycologia 93, 689–703.[CrossRef]

Pfaller, M. A., Messer, S. A., Hollis, R. J. & Jones, R. N., Sentry Participants Group (2002). Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 46, 1032–1037.[Abstract/Free Full Text]

Ramani, R., Hazarika, P., Kapadia, R. D. & Shivananda, P. G. (1994). Invasive maxillary aspergillosis in an otherwise healthy individual. Ear Nose Throat J 73, 420–422.[Medline]

Rao, K. & Saha, V. (2000). Medical management of Aspergillus flavus endocarditis. Pediatr Hematol Oncol 17, 425–427.[CrossRef][Medline]

Raper, K. B. & Fennel, D. I. (1965). The Genus Aspergillus. Baltimore: Williams & Wilkins.

Rath, P. M. (2001). Phenotypic and genotypic characterization of reference strains of the genus Aspergillus. Mycoses 44, 65–72.[CrossRef][Medline]

Rath, P. M. & Ansorg, R. (1997). Value of environmental sampling and molecular typing of aspergilli to assess nosocomial sources of aspergillosis. J Hosp Infect 37, 47–53.[CrossRef][Medline]

Richard, J. L., Thurston, J. R., Peden, W. M. & Pinello, C. (1984). Recent studies on aspergillosis in turkey poults. Mycopathologia 87, 3–11.[CrossRef][Medline]

Rigo, K., Varga, J., Toth, B., Teren, J., Mesterhazy, A. & Kozakiewicz, Z. (2002). Evolutionary relationships within Aspergillus section Flavi based on sequences of the intergenic transcribed spacer regions and the 5.8S rRNA gene. J Gen Appl Microbiol 48, 9–16.[CrossRef][Medline]

Rosa, R. H., Jr, Miller, D. & Alfonso, E. C. (1994). The changing spectrum of fungal keratitis in south Florida. Ophthalmology 101, 1005–1013.[Medline]

Rudwan, M. A. & Sheikh, H. A. (1976). Aspergilloma of paranasal sinuses – a common cause of unilateral proptosis in Sudan. Clin Radiol 27, 497–502.[CrossRef][Medline]

Saito, M. & Tsurata, O. (1993). A new variety of Aspergillus flavus from tropical soil in Thailand and its aflatoxin productivity. Proc Jpn Assoc Mycotoxicol 37, 31–36.

Sakaguchi, K. & Yamada, K. (1944). On the morphology and classification of aspergilli (I). Nippon Nogeikagaku Kaishi 20, 65–73.

Samson, R. A., Hoekstra, E. S., Frisvad, J. C. & Filtenborg, O. (2000). Identification of the common food and airborne fungi, Aspergillus. In Introduction to Food and Airborne Fungi, pp. 64–97. Utrecht: Centraalbureau voor Schimmekultures.

Saravanan, K., Panda, N. K., Chakrabarti, A., Das, A. & Bapuraj, R. J. (2006). Allergic fungal rhinosinusitis: an attempt to resolve the diagnostic dilemma. Arch Otolaryngol Head Neck Surg 132, 173–178.[Abstract/Free Full Text]

Sarubbi, F. A., Jr, Kopf, H. B., Wilson, M. B., McGinnis, M. R. & Rutala, W. A. (1982). Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis 125, 33–38.[Medline]

Scheidegger, K. A. & Payne, G. A. (2003). Unlocking the secrets behind secondary metabolism: a review of Aspergillus flavus from pathogenicity to functional genomics. J Toxicol 22, 423–459.[CrossRef]

Seo, K., Akiyoshi, H. & Ohnishi, Y. (1999). Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol 43, 1017–1025.[Medline]

Singer, S., Singer, D., Ruchel, R., Mergeryan, H., Schmidt, U. & Harms, K. (1998). Outbreak of systemic aspergillosis in a neonatal intensive care unit. Mycoses 41, 223–227.[Medline]

Smith, G. (1943). Aspergillus avenaceus. Br Mycol Soc Trans 25, 24–27.

Smith, G. (1951). Aspergillus thomii. Br Mycol Soc Trans 34, 17

Speare, A. T. (1912). Fungi parasitic upon insects injurious to sugar cane. Hawaii Sugar Plant Assoc Exp Stn Pathol Physiol Ser Bull 12, 1–62.

Sridhar, M. S., Garg, P., Bansal, A. K. & Gopinathan, U. (2000). Aspergillus flavus keratitis after laser in situ keratomileusis. Am J Ophthalmol 129, 802–804.[CrossRef][Medline]

Staib, F., Rajendran, C., Mishra, S. K., Voigt, R., Lindlar, F., Hartmann, C., Weber, R. & Nowotny, P. (1983). An atypical Aspergillus flavus from a case of bronchopulmonary aspergilloma. A contribution to the cultural and serological diagnosis of A. flavus infections. Zentralbl Bakteriol Mikrobiol Hyg [A] 255, 361–367.[Medline]

Stammberger, H., Jakse, R. & Beaufort, F. (1984). Aspergillosis of the paranasal sinuses: x-ray diagnosis, histopathology, and clinical aspects. Ann Otol Rhinol Laryngol 93, 251–256.[Medline]

States, J. S. & Christensen, M. (1966). Aspergillus leporis, a new species related to A. flavus. Mycologia 58, 738–742.[CrossRef]

Sutton, D. A., Sothergill, Q. A. & Rinaldi, M. F. (2004). Aspergillus in vitro antifungal susceptibility data: new millennium trends. In Advances Against Aspergillosis, Medical Mycological Society of America, San Francisco, California, Sept 9–11, abstract no. 16. Med Mycol 43 (Suppl. 1), S1–S319.

Taj-Aldeen, S. J., Hilal, A. A. & Chong-Lopez, A. (2003). Allergic Aspergillus flavus rhinosinusitis: a case report from Qatar. Eur Arch Otorhinolaryngol 260, 331–335.[CrossRef][Medline]

Taj-Aldeen, S. J., Hilal, A. A. & Schell, W. A. (2004). Allergic fungal rhinosinusitis: a report of 8 cases. Am J Otolaryngol 25, 213–218.[CrossRef][Medline]

Tewari, J. P. (1985). A new indeterminate stromatal type in Petromyces. Mycologia 77, 114–120.[CrossRef]

Thakar, A., Sarkar, C., Dhiwakar, M., Bahadur, S. & Dahiya, S. (2004). Allergic fungal sinusitis: expanding the clinicopathologic spectrum. Otolaryngol Head Neck Surg 130, 209–216.[CrossRef][Medline]

Thom, C. & Church, M. B. (1921). Aspergillus terricola var americanus (Marchal EJ). Am J Bot 8, 125

Thom, C. & Church, M. B. (1926). The Aspergilli. Baltimore. Williams & Wilkins.

Tran-Dihn, N., Pitt, J. I. & Carter, D. A. (1999). Molecular genotype analysis of natural toxigenic and nontoxigenic isolates of Aspergillus flavus and A. parasiticus. Mycol Res 103, 1485–1490.[CrossRef]

van Burik, J. A., Colven, R. & Spach, D. H. (1998). Cutaneous aspergillosis. J Clin Microbiol 36, 3115–3121.[Free Full Text]

Vanbreuseghem, R. & Nolard, N. (1985). Variations in fungal spores in the air during the last 10 years in Belgium. Bull Mem Acad R Med Belg 140, 147–158.[Medline]

Vandecasteele, S. J., Boelaert, J. R., Verrelst, P., Graulus, E. & Gordts, B. Z. (2002). Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery. Clin Infect Dis 35, 887–890.[CrossRef][Medline]

VandenBergh, M. F., Verweij, P. E. & Voss, A. (1999). Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. Diagn Microbiol Infect Dis 34, 221–227.[CrossRef][Medline]

Varga, J., Rigo, K., Toth, B., Téren, J. & Kozakiewicz, Z. (2003). Evolutionary relationships among Aspergillus species producing economically important mycotoxins. Food Technol Biotechnol 41, 29–36.

Vonberg, R. P. & Gastmeier, P. (2006). Nosocomial aspergillosis in outbreak settings. J Hosp Infect 63, 246–254.[CrossRef][Medline]

Vujanovic, V., Smoragiewicz, W. & Krzysztyniak, K. (2001). Airborne fungal ecological niche determination as one of the possibilities for indirect mycotoxin risk assessment in indoor air. Environ Toxicol 16, 1–8.[CrossRef][Medline]

Wang, L., Yokoyama, K., Takahasi, H., Kase, N., Hanya, Y., Yashiro, K., Miyaji, M. & Nishimura, K. (2001). Identification of species in Aspergillus section Flavi based on sequencing of the mitochondrial cytochrome b gene. Int J Food Microbiol 71, 75–86.[CrossRef][Medline]

Warris, A., Gaustad, P., Meis, J. F., Voss, A., Verweij, P. E. & Abrahamsen, T. G. (2001). Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect 47, 143–148.[CrossRef][Medline]

Wong, T. Y., Fong, K. S. & Tan, D. T. (1997). Clinical and microbial spectrum of fungal keratitis in Singapore: a 5-year retrospective study. Int Ophthalmol 21, 127–130.[CrossRef][Medline]

Yagi, H. I., Gumaa, S. A., Shumo, A. I., Abdalla, N. & Gadir, A. A. (1999). Nasosinus aspergillosis in Sudanese patients: clinical features, pathology, diagnosis, and treatment. J Otolaryngol 28, 90–94.[Medline]

Yu, J. (2004). Genetics and biochemistry of mycotoxin synthesis. In Fungal Biotechnology in Agricultural, Food, and Environmental Applications, vol. 21, pp. 343–361, edited by D. K. Arora. New York: Marcel Dekker.

Yu, J., Whitelaw, C. A., Nierman, W. C., Bhatnagar, D. & Cleveland, T. E. (2004). Aspergillus flavus expressed sequence tags for identification of genes with putative roles in aflatoxin contamination of crops. FEMS Microbiol Lett 237, 333–340.[Medline]

Yu, J., Cleveland, T. E., Nierman, W. C. & Bennett, J. W. (2005). Aspergillus flavus genomics: gateway to human and animal health, food safety, and crop resistance to diseases. Rev Iberoam Micol 22, 194–202.[Medline]

Zaini, F. & Hedayati, M. T. (1995). Study of airborne fungi in the wards of 3 Tehran hospitals. J Med Council Islam Repub Iran 13, 17–21.

This article has been cited by other articles:

				S. Brun, A. Fekkar, A. Busse, D. Seilhean, M. Lecso, D. Adler, H. Prodanovic, D. Mazier, and A. Datry Aspergillus flavus Brain Abscesses Associated with Hepatic Amebiasis in a Non-neutropenic Man in Senegal Am J Trop Med Hyg, October 1, 2009; 81(4): 583 - 586. [Abstract] [Full Text] [PDF]

				B. W. Horn, G. G. Moore, and I. Carbone Sexual reproduction in Aspergillus flavus Mycologia, May 1, 2009; 101(3): 423 - 429. [Abstract] [Full Text] [PDF]

				J. E. Mabey Gilsenan, G. Atherton, J. Bartholomew, P. F. Giles, T. K. Attwood, D. W. Denning, and P. Bowyer Aspergillus Genomes and the Aspergillus Cloud Nucleic Acids Res., January 1, 2009; 37(suppl_1): D509 - D514. [Abstract] [Full Text] [PDF]

				S. Horowitz Brown, R. Zarnowski, W. C. Sharpee, and N. P. Keller Morphological Transitions Governed by Density Dependence and Lipoxygenase Activity in Aspergillus flavus Appl. Envir. Microbiol., September 15, 2008; 74(18): 5674 - 5685. [Abstract] [Full Text] [PDF]

				L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela Aspergillus Section Fumigati: Antifungal Susceptibility Patterns and Sequence-Based Identification Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1244 - 1251. [Abstract] [Full Text] [PDF]

This Article Free via Open Access: OA OA Abstract Full Text (PDF) Supplementary table Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hedayati, M. T. Articles by Denning, D. W. Search for Related Content PubMed PubMed Citation Articles by Hedayati, M. T. Articles by Denning, D. W. Agricola Articles by Hedayati, M. T. Articles by Denning, D. W.